Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT
ALL SUBJECTS IN PHASE I SAD STUDY OF LAE102 HAVE BEEN DOSED FOR THE TREATMENT OF OBESITY

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that our phase I clinical trial of LAE102 is progressing effectively. As of the date of this announcement, all subjects (64 subjects in total of 8 intravenous injection and subcutaneous injection ascending dose cohorts) of the phase I single ascending dose study (the "**SAD Study**") have been dosed. Early signs of target engagements and expected pharmacodynamic biomarker changes have been observed with a generally accepted safety profile. The phase I clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of LAE102, administered both intravenously and subcutaneously, in healthy subjects and overweight/obese subjects.

The Group plans to commence the phase I multiple ascending dose study (the "**MAD Study**") right after the completion of the SAD Study in order to further evaluate the tolerability and efficacy to accelerate the clinical and business development of LAE102. The Group targets to bring this precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control.

Given the challenging macroeconomic environment, it is clear that strict financial discipline is essential to success. The Group has implemented and will continue to implement disciplined development strategy to ensure our healthy financial position and stable cash flow performance. It allows us to fund and accelerate the clinical development of LAE102.

ABOUT LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, December 3, 2024

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.